Natera ( (NTRA) ) is experiencing volatility. Read on for a possible explanation for the stock’s unusual movement.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Natera’s share price came under pressure as investors focused on the company’s wider GAAP losses and a recent pickup in insider stock sales, which raised concerns despite otherwise positive business trends. Analysts responding to the news maintained a generally upbeat long‑term view, highlighting Natera’s strong position in minimal residual disease testing through its Signatera platform, growing reimbursement and adoption, improving margins, and solid revenue growth prospects. They also noted a new collaboration that will use Signatera in a pivotal colorectal cancer trial and expressed confidence in robust fourth‑quarter results and a favorable 2026 outlook, leading them to adjust their price targets accordingly rather than abandon their bullish stance.
More about Natera
YTD Price Performance: 8.58%
Average Trading Volume: 1,332,346
Technical Sentiment Signal: Buy
Current Market Cap: $32.84B
For further insights into NTRA stock on TipRanks’ Stock Analysis page.
See more of today’s top stock gainers and losers.